Q4 Earnings Estimate for SRPT Issued By William Blair

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Investment analysts at William Blair issued their Q4 2025 earnings per share estimates for shares of Sarepta Therapeutics in a research note issued on Monday, January 27th. William Blair analyst S. Corwin anticipates that the biotechnology company will post earnings per share of $3.60 for the quarter. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.49 per share.

Other research analysts have also issued reports about the stock. StockNews.com lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. Evercore ISI decreased their price target on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating for the company in a research note on Thursday, November 7th. Robert W. Baird lowered their price objective on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a report on Thursday, November 7th. HC Wainwright reiterated a “sell” rating and set a $75.00 target price on shares of Sarepta Therapeutics in a report on Thursday. Finally, Piper Sandler lowered their target price on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a research note on Wednesday, November 27th. One research analyst has rated the stock with a sell rating, two have given a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $178.71.

Sarepta Therapeutics Price Performance

Shares of Sarepta Therapeutics stock opened at $115.45 on Thursday. The business has a 50 day moving average of $122.73 and a 200 day moving average of $127.59. Sarepta Therapeutics has a 52 week low of $102.15 and a 52 week high of $173.25. The company has a market cap of $11.03 billion, a PE ratio of 92.36 and a beta of 0.77. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 1,636 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total transaction of $205,399.80. Following the transaction, the director now owns 5,880 shares of the company’s stock, valued at $738,234. The trade was a 21.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the sale, the director now directly owns 22,840 shares of the company’s stock, valued at approximately $2,851,345.60. This trade represents a 31.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Sarepta Therapeutics

Several large investors have recently made changes to their positions in the business. Van ECK Associates Corp grew its position in shares of Sarepta Therapeutics by 24.4% during the fourth quarter. Van ECK Associates Corp now owns 84,834 shares of the biotechnology company’s stock worth $10,315,000 after purchasing an additional 16,658 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its stake in Sarepta Therapeutics by 16,717.7% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 85,434 shares of the biotechnology company’s stock worth $10,602,000 after purchasing an additional 84,926 shares during the period. Louisiana State Employees Retirement System grew its holdings in Sarepta Therapeutics by 0.4% during the 4th quarter. Louisiana State Employees Retirement System now owns 26,500 shares of the biotechnology company’s stock valued at $3,222,000 after buying an additional 100 shares in the last quarter. Sovran Advisors LLC bought a new stake in shares of Sarepta Therapeutics during the fourth quarter valued at approximately $3,210,000. Finally, Newbridge Financial Services Group Inc. bought a new stake in shares of Sarepta Therapeutics during the fourth quarter valued at approximately $36,000. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.